Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Zila

This article was originally published in The Tan Sheet

Executive Summary

Zila: Signs definitive agreement to acquire Ester-C maker Oxycal Labs, the Phoenix, Ariz.-based dental healthcare product company announces. Oxycal, a privately held, Prescott, Ariz.-based maker of the patented form of vitamin C, manufactures Ester-C by combining vitamin C with either calcium, magnesium, zinc, sodium or potassium to produce a compound that is less acidic and contains vitamin C metabolites. Oxycal distributes the ingredient in bulk form to over 100 supplement manufacturers. Zila, which markets the Zilactin brand of oral analgesics as its only OTC offering, says "Oxycal is highly profitable," noting the firm "holds important technology patents which...have potential applications in the pharmaceutical industry." Completion of the agreement must be ratified by Oxycal shareholders, who are scheduled to vote around Nov. 10. Terms were not disclosed...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087755

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel